Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.

von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P

Diabetic medicine : a journal of the British Diabetic Association15 Oct 2014Cited by 61 (Europe PMC)

PMID25251901DOI10.1111/dme.12594PepBankPUB-25251901

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, 24-h systolic blood pressure rose by 10 mmHg on day 3 of liraglutide treatment.
In plain wordsIn adults with diabetes and high blood pressure, 24-hour systolic blood pressure rose by 10 mmHg after 3 days of liraglutide.
Peptide
Liraglutide
Outcome
Increase24-h systolic blood pressure at day 3
Study
n = 31
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Measurements
24-h SBP change
10 mmHg
day 3
Source sentences
Summary
Twenty-four-h SBP increased by 10 mmHg on day 3 (P = 0.008)
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190101
02HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, 24-h systolic blood pressure rose by 7 mmHg on day 7 of liraglutide 0.6 mg/day.
In plain wordsIn adults with diabetes and high blood pressure, 24-hour systolic blood pressure rose by 7 mmHg after 7 days of liraglutide.
Peptide
Liraglutide
Outcome
Increase24-h systolic blood pressure at day 7
Study
n = 31
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.6 mg/day · 7 weeksAs given in this study (human).
Measurements
24-h SBP change
7 mmHg
day 7
Source sentences
Summary
7 mmHg on day 7 (P = 0.033, 0.6 mg/day).
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190102
03HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, 24-h systolic blood pressure was 7 mmHg lower than baseline on day 29 of liraglutide 1.8 mg/day, which was not significant.
In plain wordsIn adults with diabetes and high blood pressure, systolic pressure was 7 mmHg lower on day 29, but this was not a significant change.
Peptide
Liraglutide
Outcome
No significant change24-h systolic blood pressure at day 29
Study
n = 31
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.8 mg/day · 7 weeksAs given in this study (human).
Measurements
24-h SBP difference from baseline
−7 mmHg
day 29
Source sentences
Summary
On day 29, (1.8 mg/day), 24-h SBP was 7 mmHg lower compared with baseline (P = 0.11).
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190103
04HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, 24-h blood pressure at the end of the treatment period (day 49) was equivalent to baseline.
In plain wordsIn adults with diabetes and high blood pressure, 24-hour blood pressure was back at the baseline level at the end of liraglutide treatment.
Peptide
Liraglutide
Outcome
No significant change24-h blood pressure at day 49
Study
n = 31
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Source sentences
Summary
Following the treatment period (day 49) and after washout (day 70), 24-h BP was equivalent to baseline
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190104
05HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, 24-h blood pressure after the washout period (day 70) was equivalent to baseline.
In plain wordsIn adults with diabetes and high blood pressure, 24-hour blood pressure was at the baseline level after stopping liraglutide.
Peptide
Liraglutide
Outcome
No significant change24-h blood pressure after washout (day 70)
Study
n = 31
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Source sentences
Summary
Following the treatment period (day 49) and after washout (day 70), 24-h BP was equivalent to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190105
06HumanNon-randomized trialMechanism
In adults with type 2 diabetes and hypertension, liraglutide reduced extracellular volume by 2.0 l.
In plain wordsIn adults with diabetes and high blood pressure, liraglutide reduced the body's extracellular fluid volume by 2.0 litres.
Peptide
Liraglutide
Outcome
DecreaseExtracellular volume
Study
n = 31
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Measurements
Extracellular volume change
−2 l
Source sentences
Summary
In addition, extracellular volume (ECV) was reduced by 2.0 l [95% confidence interval (CI) = 1.0-3.1 l, P < 0.001]
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190106
07HumanNon-randomized trialMechanism
In adults with type 2 diabetes and hypertension, liraglutide reduced midregional-pro-atrial natriuretic peptide by 20%.
In plain wordsIn adults with diabetes and high blood pressure, liraglutide lowered the heart hormone marker MR-proANP by 20%.
Peptide
Liraglutide
Outcome
DecreaseMR-proANP
Study
n = 31
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Measurements
MR-proANP change
−20%
Source sentences
Summary
midregional-pro-atrial natriuretic peptide (MR-proANP) was reduced by 20% (95% CI = 12-28%, P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190107
08HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, liraglutide reduced urinary albumin excretion by 30%.
In plain wordsIn adults with diabetes and high blood pressure, liraglutide reduced albumin loss in urine by 30%.
Peptide
Liraglutide
Outcome
DecreaseUrinary albumin excretion
Study
n = 31
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Measurements
Urinary albumin excretion change
−30%
Source sentences
Summary
Also, urinary albumin excretion declined by 30% (95% CI = 12-44%, P = 0.003)
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190108
09HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, liraglutide treatment lowered the glomerular filtration rate by 11 ml/min/1.73 m2.
In plain wordsIn adults with diabetes and high blood pressure, liraglutide lowered kidney filtration rate by 11 ml/min.
Peptide
Liraglutide
Outcome
DecreaseGlomerular filtration rate
Study
n = 31
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Measurements
GFR change
−11 ml/min/1.73 m(2)
Source sentences
Summary
GFR by 11 ml/min/1.73 m(2) (95% CI = 7.2-14.4 ml/min/1.73 m(2) , P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190109
10HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes and hypertension, liraglutide reduced fractional albumin excretion by 29%.
In plain wordsIn adults with diabetes and high blood pressure, liraglutide reduced the fraction of albumin lost in urine by 29%.
Peptide
Liraglutide
Outcome
DecreaseFractional albumin excretion
Study
n = 31
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 7 weeksAs given in this study (human).
Measurements
Fractional albumin excretion change
−29%
Source sentences
Summary
fractional albumin excretion by 29% (95% CI = 3-48%, P = 0.032).
2 context sentences(design, population, supporting numbers)
Summary · context
We used an open-label, single-centre trial; 31 participants with Type 2 diabetes and hypertension completed the study.
Summary · context
All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21-day washout period.
Report a problemFND-2525190110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.